 Pasternak: Merck Will Stay in Heart Disease Research
11-10-2008 |
13:42 hs.
|
According to Richard Pasternak, head of cardiovascular clinical research of the Whitehouse Station based Merck & Co. they currently have under research 8 new compounds. Pasternak’s remarks were made at the Annual Congress of the American Heart Association currently undergoing in New Orleans. With almost 30 percent of the US market share for heart diseases drugs. Merck & Co. Revealed their strong commitment to research and development. The company currently makes roughly $7 billion of its $24 billion in annual revenue from the blood pressure drugs Cozaar, Hyzaar and Vasotec and its cholesterol drugs Vytorin, Zetia and Zocor.  Publish comment:
|
Estimated reading time: 0:30
Word count: 677
Most read articles Glenmark Gets FDA Approval For Generic Imuran (GSK) // 01/05/2009 Lilly Signs a Licensing Agreement with BioMS to Develop MS Drug Dirucotide // 12/30/2008 Novartis AG Gets Rights for AlphaVax Inc.’s Cytomegalovirus Vaccine for $20 Million // 12/30/2008
2008, Will be the Year of...
|
